Articles related to PROSTATE CANCER

Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.

In a significant advancement, one physician’s minimally invasive technique for treating membranous urethral strictures post-radiation therapy showcases promising outcomes, including improved urethral patency and reduced operative complications, marking a pivotal shift in patient management strategies.

In the phase 3 GETUG-AFU 18 trial, high-dose radiotherapy (80 Gy) combined with long-term androgen deprivation therapy markedly improved 10-year progression-free and overall survival in high-risk prostate cancer patients, without additional toxicity.

In a landmark study, researchers found that each doubling of PSA levels in men over 70 doubles the risk of prostate cancer death, highlighting the critical need for tailored screening approaches in older patients.

In a novel approach to combat metastatic castration-resistant prostate cancer, ODM-208, targeting cytochrome P450 11A1, has shown promising results in reducing prostate-specific antigens and testosterone levels, offering new hope in a challenging therapeutic area.

In a recent high-profile case, a jury awarded over $2 million in a robot-assisted prostate surgery lawsuit, underlining the critical importance of surgical precision and accountability in advanced medical procedures.